AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer NSCLC

Interventions: Drug: Durvalumab
Drug: Olaparib
Drug: Placebo for Olaparib
Drug: Nab-paclitaxel+carboplatin
Drug: Gemcitabine+carboplatin
Drug: Pemetrexed+carboplatin
Drug: Gemcitabine+cisplatin
Drug: Pemetrexed+cisplatin

First Posted Date: 2018-12-14

Last Posted Date: 2025-03-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 401

Registration Number: NCT03775486

Locations: 🇬🇧
Research Site, Hull, United Kingdom

A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately.

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)
Drug: Treatment B (Budesonide metered dose inhaler)
Drug: Treatment C (Albuterol Sulfate metered dose inhaler)

First Posted Date: 2018-12-11

Last Posted Date: 2019-05-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 91

Registration Number: NCT03772223

Locations: 🇬🇧
Research Site, London, United Kingdom

A Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Anti-inflammatory Effect of Inhaled AZD0449

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: AZD0449
Drug: Placebo

First Posted Date: 2018-12-06

Last Posted Date: 2024-08-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 131

Registration Number: NCT03766399

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: 1L treatment
Drug: 2L Treatment
Drug: 3L treatment

First Posted Date: 2018-12-03

Last Posted Date: 2020-05-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 141

Registration Number: NCT03761901

Locations: 🇧🇪
Research Site, Yvoir, Belgium

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

Phase 2

Terminated

Conditions: Crohn's Disease
IBD

Interventions: Drug: Brazikumab low dose
Drug: Brazikumab high dose
Drug: Placebo
Drug: Humira®

First Posted Date: 2018-11-29

Last Posted Date: 2023-11-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 89

Registration Number: NCT03759288

Locations: 🇬🇧
Research Site, West Bromwich, United Kingdom

Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy

Phase 2

Completed

Conditions: Painful Diabetic Neuropathy

Interventions: Drug: MEDI7352
Other: Placebo

First Posted Date: 2018-11-28

Last Posted Date: 2023-09-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 112

Registration Number: NCT03755934

Locations: 🇬🇧
Research Site, Stockton-on-Tees, United Kingdom

Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.

Phase 2

Terminated

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: AZD4831

First Posted Date: 2018-11-28

Last Posted Date: 2021-07-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 41

Registration Number: NCT03756285

Locations: 🇸🇪
Research Site, Stockholm, Sweden

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

Phase 1

Active, not recruiting

Conditions: Triple Negative Breast Neoplasms

Interventions: Drug: Durvalumab
Drug: Capivasertib
Drug: Trastuzumab deruxtecan
Drug: Oleclumab
Drug: Datopotamab deruxtecan
Drug: Paclitaxel

First Posted Date: 2018-11-15

Last Posted Date: 2025-01-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 243

Registration Number: NCT03742102

Locations: 🇬🇧
Research Site, Oxford, United Kingdom

A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold
Drug: BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold

First Posted Date: 2018-11-14

Last Posted Date: 2018-11-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 10

Registration Number: NCT03740373

Locations: 🇬🇧
Research Site, Pentrebach, United Kingdom

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Phase 3

Active, not recruiting

Conditions: Advanced Ovarian Cancer

Interventions: Drug: Bevacizumab
Drug: Durvalumab
Drug: Olaparib
Drug: Placebo olaparib
Drug: Durvalumab placebo
Drug: Carboplatin+Paclitaxel

First Posted Date: 2018-11-09

Last Posted Date: 2025-01-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 1407

Registration Number: NCT03737643

Locations: 🇹🇷
Research Site, Izmir, Turkey

Home Terms & Conditions Privacy Policy